S-Adenosyl-Methionine

PreclinicalSmall molecule

NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

S-Adenosyl-Methionine is one of 19 small molecule programs targeting Abdominal pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Abdominal PainActive, not recruiting

Hepatic CarcinomaUnknown status

Abdominal PainPreclinical

Active, not recruiting

Hepatic CarcinomaPreclinical

Unknown status

Competition

Competitive Landscape

18 competitors in Abdominal Pain

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Approved

1 2

Lopid

Niacor

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

1 5

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 6

Xylocaine

MMEDRx USA, Inc.

Approved

1 7

Naropin

FFresenius Kabi USA, LLC

Approved

—8

Proair HFA

GGlaxo Dba Glaxosmithkline

Chirocaine

Orgovyx

Sumitomo Pharma America, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital··NCT05701553·20 enrolled

Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma

Unknown status·—·Phase 1·NCT02586285·300 enrolled

Abdominal pain1 trial

Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children

Completed·—·N/A·NCT00694564·8 enrolled

Cirrhosis1 trial

SAMe to Treat Biliary Cirrhosis Symptoms

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00125281·50 enrolled

Hepatic Carcinoma1 trial

Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma

Unknown status·BBeijing Insight Science & Technology Co. Ltd.·N/A·NCT03178929·207 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for S-Adenosyl-Methionine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S-Adenosyl-Methionine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S-Adenosyl-Methionine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

S-Adenosyl-Methionine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Abdominal pain1 trial

Cirrhosis1 trial

Hepatic Carcinoma1 trial

References

Drug Info

Quick Facts

Related News